Medicine and Dentistry
Adverse Event
8%
ANCA Associated Vasculitis
80%
Anticoagulation
5%
Apoplexy
6%
Autoantibodies
25%
Biological Marker
16%
Biopsy
23%
Biopsy Sample
8%
Consultation
9%
Continuous Positive Airway Pressure
25%
Controlled Clinical Trial
25%
Coronavirinae
10%
COVID-19
62%
Disease Activity
25%
Diseases
39%
Glomerulonephritis
53%
Glomerulus
16%
Glucocorticoid
25%
Health Care Cost
8%
High Risk Population
5%
Idiopathic Pulmonary Fibrosis
8%
Immunoglobulin A Nephropathy
25%
Immunosuppressive Treatment
17%
Infection
11%
Intensive Care
25%
Interim Analysis
25%
Irbesartan
18%
Kaplan Meier Method
5%
Mortality Rate
5%
Nephrologist
12%
Nephrology
25%
Neutrophil
25%
Pandemic
6%
Patient Experience
8%
Patient-Reported Outcome
25%
Personal Experience
25%
Predictive Modeling
8%
Prognostication
5%
Proteinuria
6%
Raman Spectrometry
25%
Renal Biopsy
11%
Renal Replacement Therapy
25%
Risk Stratification
25%
Rituximab
8%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Sparsentan
25%
Spectroscopy
8%
Spontaneous Remission
10%
Telehealth
25%
Urine Sampling
27%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
8%
ANCA Associated Vasculitis
100%
Controlled Clinical Trial
25%
Coronavirinae
5%
Cross-Sectional Study
5%
Disease
47%
Disease Duration
8%
Glucocorticoid
28%
Immunoglobulin A Nephropathy
25%
Infection
6%
Irbesartan
18%
Proteinuria
6%
Rituximab
11%
SARS Coronavirus
5%
Sparsentan
25%
Symptom
8%
